S2Medical

What S2Medical does

S2Medical AB (publ) is a Swedish biomed-tech company founded in 2013 and headquartered in Linköping, Sweden, with a sales office in Dubai, UAE serving the MENA region. The company develops and manufactures medical products for wound healing, infection control, and cosmeceuticals, operating under the brand "The Wound Healing Company." Its core proprietary technology is Eiratex®, a biosynthetic polymer composed of engineered sugar molecules with a nanostructure that mimics natural collagen, providing biocompatibility, transparency, mechanical strength, and breathability. The portfolio includes Epiprotect® (wound dressing technology, now acquired by ABENA Group with S2Medical continuing production), IvaQ® (CE-marked negative-pressure wound therapy system with patented absorbent tubing), Instagraft® (patented single-use micro-transplant skin grafting device achieving up to 1:100 donor-to-transplant ratio), ADMERCIN™ (antimicrobial peptide platform targeting ESKAPE pathogens and drug-resistant bacteria), and Symbiovance™ (peptide-based skincare for microbiome balance). The company has approximately 5.1 million EUR in cumulative research grant funding and operates an in-house manufacturing facility with five cleanroom areas, capable of producing up to 30,000 dressings per month under ISO 13485 and MDR (EU) 2017/745 compliance.

S2Medical pursues a multi-channel go-to-market model combining direct sales in Scandinavia with a distributor network covering the UK, Italy, France, Germany, and approximately ten markets across the Middle East, Asia, and Africa. The company also operates the S2Clinic wound healing center in Linköping, which generates service revenue, demonstrates products, and conducts clinical studies. Revenue streams span product sales (Epiprotect, instaQrett, BIOPAD), B2B licensing (Eiratex to ABENA, Symbiovance, ADMERCIN co-development), distribution margins on third-party products, and clinic services. The company is publicly listed on Nasdaq First North Growth Market Stockholm under ticker S2M and has raised capital through multiple rights issues since its 2018 IPO, including 21.2 MSEK in 2020 and 30.1 MSEK in 2022, indicating ongoing capital dependency. Geographic restrictions in the listed materials explicitly exclude the USA, UK, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, and South Africa, which constrains the addressable market. The company serves hospitals, burn centers, wound care clinics, and healthcare providers, with the primary customer segment being healthcare institutions treating chronic wounds, burns, and surgical incisions.

Name

S2Medical

Legal name

S2Medical AB (publ)

Website

https://s2m.se

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

S2Medical AB (publ) is a Swedish biomed-tech company that develops and manufactures wound healing, infection control, and cosmeceutical products, serving hospitals, clinics, and healthcare providers across Europe, the Middle East, Asia, and Africa.

Ownership category

akta.pro rank

Product category

Wound Care Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Wound Care & Diabetic Foot Infection (HLAKAGAK)

Keywords

• Advanced wound care
• Biomaterial medical devices
• Negative pressure therapy
• Antimicrobial peptides
• Wound healing dressings

Headquarters

HQ city

Linköping

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Product sales: Sale of wound healing medical products including Epiprotect, instaQrett, BIOPAD, and other wound care solutions through direct sales and distributor network across Europe, Middle East, Asia, and Africa.
2. Technology licensing: Licensing of proprietary technologies including the Eiratex material technology to ABENA for Epiprotect production and continued commercialization through ABENA's global network. Also positioned for B2B licensing of Symbiovance technology to cosmetic brands.
3. ADMERCIN pharmaceutical partnerships: Designed for co-development and licensing to pharmaceutical partners for clinical translation and market adoption in antimicrobial therapeutics addressing antibiotic-resistant infections.
4. Clinic services: Revenue generated through S2Clinic wound healing center in Linköping offering treatments for chronic wounds, consultations, and clinical studies using S2Medical's product portfolio.
5. Distribution partnerships: Global distribution of third-party products including instaQrett as global distributor, and BIOPAD distribution in MENA and Philippines.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Core offering

S2Medical manufactures and commercializes proprietary biomaterial-based wound healing medical devices, including wound dressings (Epiprotect), a negative pressure wound therapy system (IvaQ), a skin transplantation device (Instagraft), and an antimicrobial peptide platform (ADMERCIN). The company also distributes complementary wound care products (instaQrett, BIOPAD) and operates S2Clinic, a wound healing center in Linköping. The company pursues technology licensing partnerships (e.g., Symbiovance in cosmeceuticals).

Product overview

S2Medical is a Swedish biomed-tech innovator operating as 'The Wound Healing Company,' developing and commercializing a portfolio of medical technologies focused on wound healing, infection control, and cosmeceuticals. The core product portfolio includes Epiprotect® (wound healing dressing acquired by ABENA but with continued S2Medical production involvement), IvaQ® (CE-marked negative pressure wound therapy system), Instagraft® (patented skin grafting device), ADMERCIN™ (antimicrobial peptide platform for antibiotic-resistant infections), and Symbiovance™ (peptide-based functional skincare). The proprietary Eiratex® biosynthetic polymer material underpins the Epiprotect® dressing technology. S2Medical also distributes complementary products including instaQrett® (skin substitutes), BIOPAD® (collagen products), and YNOLENS™/NO SMELL (odor eliminator). The company operates manufacturing facilities in Linköping, Sweden with five cleanroom areas and maintains a sales office in Dubai, UAE.

Differentiator

Problem solved

Functional benefit

Brands

• Epiprotect: Innovative wound healing technology acquired by ABENA. Creates optimal environment for tissue recovery, reduces infection risk and pain while accelerating healing. Made from Eiratex material.
• IvaQ
• Instagraft
• ADMERCIN
• Symbiovance
• Eiratex
• instaQrett
• YNOLENS / No Smell
• BIOPAD

Products and services

• Epiprotect Innovative wound healing technology that creates an optimal environment for tissue recovery, reduces risk of infection and pain, and accelerates healing. Made from Eiratex biosynthetic polymer. Now acquired by ABENA, with S2Medical remaining involved in production and continued growth.
• IvaQ® CE-marked next-generation negative pressure wound therapy (NPWT) system designed to manage deep wounds and surgical incisions while promoting granulation tissue formation. Features patented absorbent tubing that reduces the need for unnecessary dressing changes. Compact, portable, single-use system for healthcare providers and patients with complex wounds.
• Instagraft® Patented single-use medical device for treating chronic and complicated wounds using micro-transplants from the patient's own skin without creating new wounds. Increases donor-to-transplant ratio up to 1:100, making advanced skin transplantation accessible in non-specialist healthcare settings.
• ADMERCIN™
• Symbiovance™
• instaQrett®
• BIOPAD®
• YNOLENS™ / NO SMELL
• Eiratex®
• S2Clinic wound healing center Wound healing clinic in Linköping treating chronic wounds using S2Medical's product portfolio. Generates revenue through treatments, consultations, and clinical studies while demonstrating products and serving as a world-leading wound healing center.

Quantifiable outcome

• Up to 30,000 dressings per month production capacity in state-of-the-art facility with five cleanroom areas
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• ABENA GroupcoreOEM/ Whitelabel/ Licensing PartnerS2Medical sold the Epiprotect technology to ABENA, a family-owned world-leading healthcare company. S2Medical remains deeply involved in the production and continued growth of Epiprotect. Eiratex material technology is now owned by Epiprotect AB (a company within ABENA Group) while S2Medical continues manufacturing the material in its Linköping facility.
• Eyracure ABminorOthersS2Medical held 22.3% ownership in Eyracure AB. The company filed for bankruptcy in June 2026. S2Medical's stake was already written down to 0 kronor in the 2025 year-end accounts, so the bankruptcy has no further impact.
• Leading universities and research institutionscoreStrategic or Co-development PartnerS2Medical collaborates with industrial PhD students, postdocs, professors, and international research teams to develop products and find solutions for future product portfolio. Interdisciplinary collaborations at forefront of biomaterials, regenerative medicine, and infection control.
• Curenc ABcoreStrategic or Co-development PartnerAcquisition agreement signed in October 2020 for Curenc AB's patented antimicrobial peptide technology. The technology was intended to be commercialized through multiple steps including a skin cream preventing bacterial spread from skin to wounds and an antibacterial version of EPIPROTECT.
• Global distributors (UK, Italy, France, Germany, MENA, Asia, Africa)coreChannel Partner/ Reseller/ DistributorEstablished distributor network covering European markets (UK, Italy, France, Germany) and approximately 10 markets outside Europe in Middle East, Asia, and Africa. Distributors for instaQrett globally and BIOPAD in MENA and Philippines.
• SilverlonminorChannel Partner/ Reseller/ DistributorS2Medical has been a distributor since 2019 of Silverlon, an antimicrobial product. This filled the gap in their own antimicrobial product line before acquiring Curenc AB's AMP technology.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Integra LifeSciences: Developer of regenerative tissue technologies and wound matrices (Integra dermal regeneration template); directly comparable regenerative wound-healing IP and customer base.
• Organogenesis: U.S. regenerative-medicine company selling skin substitutes (Apligraf, Dermagraft) and advanced wound-care products; closely comparable technology platform for skin regeneration and chronic wound healing.
• Mölnlycke Health Care: Swedish-headquartered global wound-care and surgical solutions company with Mepilex-style dressings and wound-healing portfolios; directly comparable specialty wound-care focus from the same home market.
• Urgo Medical: European advanced wound-care specialist (UrgoStart, Urgocell) competing across chronic-wound dressings and NPWT adjacencies relevant to IvaQ and Epiprotect.
• MiMedx: U.S. company commercializing amniotic membrane-based skin substitutes and wound-care grafts; overlapping regenerative wound-healing technology and clinical indications.

Broad incumbents

• ConvaTec: Established wound-care major with AQUACEL dressings, skin substitutes and ostomy products; competes directly across S2Medical's dressing and regenerative segments.
• 3M Health Care: Diversified medical-products giant with substantial advanced wound-care and skin-health portfolios; broad incumbent competing across multiple S2Medical product categories.
• Coloplast: Danish wound-care and ostomy specialist with Biatain-style advanced dressings; comparable Nordic wound-care peer across product categories and geographies.
• Smith+Nephew: Global medical-device incumbent with large Advanced Wound Management franchise (ALLEVYN, PICO NPWT), competing across the same wound-care categories S2Medical addresses.

Others

• ABENA: Family-owned global healthcare company that acquired S2Medical's Epiprotect technology; functions as S2Medical's primary commercial partner and global distributor for the lead asset.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about S2Medical